Type 2 diabetes
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this clinical study and sign the informed consent; 2. Meet the World Health Organization (WHO) diagnostic criteria for type 2 diabetes; 3. Gender is not limited, age 20-75 years old; 4. Patients with HbA1c of 6.5-9.5% who did not receive antihyperglycemic drugs (AHA) for >= 8 weeks before screening, and started to use empagliflozin or hepagliflozin monotherapy; 5. Fasting C-peptide >= 1.0 ng/ml; 6. Fasting blood sugar < 13.3 mmol/L.
Exclusion criteria
Exclusion criteria: 1. Hyperglycemia due to other diseases; 2. Type 1 diabetes; 3. Severe diabetic complications, such as diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome or lactic acidosis; 4. Hypertension that is still difficult to control after using 3 kinds of antihypertensive drugs (systolic blood pressure/diastolic blood pressure >= 160/100 mmHg); 5. Hypersensitivity to Hepagliflozin and Empagliflozin; 6. Severe impairment of liver and kidney function (glomerular filtration rate [eGFR] < 60 mL/min/1.73m2; aspartate aminotransferase [AST], alanine aminotransferase [ALT] or alkaline phosphate Enzyme levels three times higher than the upper limit of normal); have any other uncontrolled endocrine disease other than type 2 diabetes; 7. Patients with myocardial infarction, unstable angina, cardiac surgery or revascularization (coronary artery bypass grafting/percutaneous transluminal coronary angioplasty) or congestive heart failure within 6 months before the trial New York Heart Association Class III or IV medical history; cerebrovascular accident or serious infection; immunocompromised or history of cancer; 8. Current continuous systemic administration of corticosteroids or immunosuppressants; 9. Pregnancy/lactation; 10. Participated in other research projects in the last 3 months or participated in two or more projects in 1 year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin-like growth factor 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin-like growth factor binding protein (Insulin-like growth factor binding protein-3, insulin-like growth factor binding protein-1);Telomere length;Insulin function (HOMA-IR, HOMA-ß);Inflammatory indicators (interleukin-6, interleukin-8, tumor necrosis factor-a, C-reactive protein);ß-hydroxybutyric acid;Body composition indicators (lean body mass, body fat and percentage body fat); | — |
Countries
China
Contacts
Public ContactXu Jixiong
The First Affiliated Hospital of Nanchang University
Outcome results
None listed